These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 19104179)

  • 21. Aprotinin, an antifibrinolytic drug, attenuates bradykinin-induced permeability in conscious rats via platelets and neutrophils.
    O'Brien JG; Battistini B; Farmer P; Johnson RJ; Zaharia F; Plante GE; Sirois P
    Can J Physiol Pharmacol; 1997 Jun; 75(6):741-9. PubMed ID: 9276158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprotinin in cardiac surgery.
    Sodha NR; Boodhwani M; Bianchi C; Ramlawi B; Sellke FW
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):151-60. PubMed ID: 16509811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [On coagulation inhibiting effect of proteinase inhibitors from animal organs].
    Gülzow M; Schulz K
    Z Gesamte Inn Med; 1967 Nov; 22(21):641-7. PubMed ID: 5302275
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparative study of the immune modulating properties of antifibrinolytics in cardiac surgery.
    Later AF; Bruggemans EF; Romijn FP; van Pelt J; Klautz RJ
    Cytokine; 2013 Feb; 61(2):438-44. PubMed ID: 23186831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of antifibrinolytic agents on the life span of fibrin sealant.
    Pipan CM; Glasheen WP; Matthew TL; Gonias SL; Hwang LJ; Jane JA; Spotnitz WD
    J Surg Res; 1992 Oct; 53(4):402-7. PubMed ID: 1383616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and risks of aprotinin use during cardiac surgery.
    Kristeller JL; Roslund BP; Stahl RF
    Pharmacotherapy; 2008 Jan; 28(1):112-24. PubMed ID: 18154481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On the anticoagulant effect of some inhibitors of fibrinolysis].
    Donner L; Housková J
    Sb Lek; 1969 Apr; 71(4):85-91. PubMed ID: 5305357
    [No Abstract]   [Full Text] [Related]  

  • 28. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
    Walker JB; Bajzar L
    J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.
    Bajaj MS; Ogueli GI; Kumar Y; Vadivel K; Lawson G; Shanker S; Schmidt AE; Bajaj SP
    J Biol Chem; 2011 Feb; 286(6):4329-40. PubMed ID: 21115497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.
    Day JR; Landis RC; Taylor KM
    Semin Cardiothorac Vasc Anesth; 2006 Jun; 10(2):132-42. PubMed ID: 16959740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
    Dong Y; Nuttall GA; Oliver WC; Agarwal S; Ereth MH
    J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antifibrinolytic agents and repeat open-heart surgery: a comparison of tranexamic acid and low dose aprotinin].
    Ait Houssa M; Selkane C; Amahzoune B; El Bekkali Y; Wahid FA; Moutaki Allah Y; Boulahya A; Ibat D; Drissi M; Azendour H; Elkirat A
    Ann Cardiol Angeiol (Paris); 2007 Dec; 56(6):308-12. PubMed ID: 17976511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current antifibrinolytic therapy for coronary artery revascularization.
    Trudell J; McMurdy N
    AANA J; 2008 Apr; 76(2):121-4. PubMed ID: 18478817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrin deposition in the ribbit kidney produced by protease inhibitors.
    Beller FK; Mitchell PS; Gorstein F
    Thromb Diath Haemorrh; 1967 May; 17(3-4):427-39. PubMed ID: 5301528
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery.
    Hsia TY; McQuinn TC; Mukherjee R; Deardorff RL; Squires JE; Stroud RE; Crawford FA; Bradley SM; Reeves ST; Spinale FG
    Ann Thorac Surg; 2010 Jun; 89(6):1843-52; discussion 1852. PubMed ID: 20494037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor.
    Lisman T; Adelmeijer J; Huskens D; Meijers JCM
    TH Open; 2021 Jul; 5(3):e363-e375. PubMed ID: 34485811
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro simulation of thrombolysis inhibition.
    Stief TW
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):234-7. PubMed ID: 18160584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of coagulation and fibrinolysis by plasma proteinase inhibitors.
    Travis J; Salvesen G
    Behring Inst Mitt; 1983 Aug; (73):56-65. PubMed ID: 6206838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Living without aprotinin: the results of a 5-year blood saving program in cardiac surgery.
    Ranucci M; Castelvecchio S; Romitti F; Isgrò G; Ballotta A; Conti D
    Acta Anaesthesiol Scand; 2009 May; 53(5):573-80. PubMed ID: 19173686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aprotinin: antifibrinolytic and anti-inflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass.
    Donahue MA; Price PM
    Dynamics; 2002; 13(3):16-23. PubMed ID: 12640841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.